Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)
NCT02006043 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54
Last updated 2015-07-03
Summary
evaluate Erlotinib efficacy and safety as the 2nd/3rd line treatment in advanced or recurrent NSCLC with EGFR wild type and without c-met expression
Conditions
Interventions
- DRUG
-
Erlotinib 150mg
Sponsors & Collaborators
-
Li Zhang
lead OTHER
Principal Investigators
-
Li Zhang · Sun Yat-sen University
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-12-31
- Primary Completion
- 2016-12-31
Countries
- China
Study Locations
More Related Trials
-
Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21
NCT01714908 ·Status: UNKNOWN ·Phase: PHASE2
-
Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer
NCT01407822 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation
NCT00874419 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
NCT06300424 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation
NCT02095782 ·Status: TERMINATED ·Phase: PHASE2
-
Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations
NCT01410214 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer
NCT00663689 ·Status: UNKNOWN ·Phase: PHASE2
-
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
NCT01565538 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
NCT06863506 ·Status: RECRUITING ·Phase: PHASE2
-
Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation
NCT02001896 ·Status: UNKNOWN ·Phase: PHASE3
-
Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca
NCT02036359 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy
NCT01297101 ·Status: TEMPORARILY_NOT_AVAILABLE
-
Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
NCT01024413 ·Status: COMPLETED ·Phase: PHASE3
-
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
NCT04687241 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
NCT00567359 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
NCT04685070 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
NCT01887886 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
NCT02468661 ·Status: TERMINATED ·Phase: PHASE1
-
Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR
NCT04785742 ·Status: UNKNOWN ·Phase: PHASE2
-
Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc
NCT01955421 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
NCT03240393 ·Status: WITHDRAWN ·Phase: PHASE2
-
Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation
NCT01204307 ·Status: COMPLETED ·Phase: PHASE2
-
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
NCT06092086 ·Status: RECRUITING ·Phase: PHASE2
-
A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR
NCT02178397 ·Status: TERMINATED ·Phase: PHASE3
-
Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.
NCT05946460 ·Status: RECRUITING ·Phase: PHASE2